CN111565759B - 纳米载体及用途 - Google Patents

纳米载体及用途 Download PDF

Info

Publication number
CN111565759B
CN111565759B CN201880077921.4A CN201880077921A CN111565759B CN 111565759 B CN111565759 B CN 111565759B CN 201880077921 A CN201880077921 A CN 201880077921A CN 111565759 B CN111565759 B CN 111565759B
Authority
CN
China
Prior art keywords
nanoparticles
solution
nanocarrier
nanoparticle
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880077921.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111565759A (zh
Inventor
O·蒂耶芒
F·卢克斯
F·罗塞蒂
V-L·陈
C·马蒂厄
M·达汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nh Agix Treatment
Original Assignee
Nh Agix Treatment
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nh Agix Treatment, Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 filed Critical Nh Agix Treatment
Publication of CN111565759A publication Critical patent/CN111565759A/zh
Application granted granted Critical
Publication of CN111565759B publication Critical patent/CN111565759B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880077921.4A 2017-10-13 2018-10-12 纳米载体及用途 Active CN111565759B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1759607 2017-10-13
FR1759607A FR3072281B1 (fr) 2017-10-13 2017-10-13 Nanovecteurs et utilisations, en particulier pour le traitement de tumeurs
PCT/FR2018/052538 WO2019073182A1 (fr) 2017-10-13 2018-10-12 Nanovecteurs et utilisations

Publications (2)

Publication Number Publication Date
CN111565759A CN111565759A (zh) 2020-08-21
CN111565759B true CN111565759B (zh) 2024-03-26

Family

ID=61873369

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880077921.4A Active CN111565759B (zh) 2017-10-13 2018-10-12 纳米载体及用途

Country Status (10)

Country Link
US (1) US11857604B2 (https=)
EP (1) EP3694560A1 (https=)
JP (1) JP7321151B2 (https=)
KR (1) KR20200071754A (https=)
CN (1) CN111565759B (https=)
AU (1) AU2018347740B2 (https=)
CA (1) CA3078763A1 (https=)
FR (1) FR3072281B1 (https=)
TW (1) TWI791640B (https=)
WO (1) WO2019073182A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
CA3148734A1 (en) * 2019-07-29 2021-02-04 Nh Theraguix High-z-element containing nanoparticles for use in the treatement of tumors
FR3116216B1 (fr) * 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
FR3116197A1 (fr) * 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
CN113941005A (zh) * 2021-10-29 2022-01-18 上海唯可生物科技有限公司 二硫键功能化的二氧化硅纳米粒子、制备、复合物、用途
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202008010019U1 (de) * 2008-02-19 2009-08-06 Guerbet Pharmazeutische Formulierung von Kontrastmitteln
CN101827614A (zh) * 2007-10-16 2010-09-08 克洛德·贝纳尔-里昂第一大学 基于镧系元素的纳米颗粒作为放射增敏剂的应用
CA2869689A1 (fr) * 2012-04-13 2013-10-17 Universite Claude Bernard Lyon 1 Nanoparticules ultrafines comme agent de contraste multimodal
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2795412B1 (fr) 1999-06-23 2001-07-13 Adir Nouveaux derives d'ammonium quaternaire, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2499496C (fr) 2002-09-19 2012-04-24 Centre National De La Recherche Scientifique - Cnrs Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles
FR2959502B1 (fr) * 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101827614A (zh) * 2007-10-16 2010-09-08 克洛德·贝纳尔-里昂第一大学 基于镧系元素的纳米颗粒作为放射增敏剂的应用
DE202008010019U1 (de) * 2008-02-19 2009-08-06 Guerbet Pharmazeutische Formulierung von Kontrastmitteln
CA2869689A1 (fr) * 2012-04-13 2013-10-17 Universite Claude Bernard Lyon 1 Nanoparticules ultrafines comme agent de contraste multimodal
JP2015518478A (ja) * 2012-04-13 2015-07-02 ユニベルシテ・クロード・ベルナール・リヨン・プルミエ マルチモーダル造影剤としての超微細ナノ粒子
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery;Zhang Q 等;《 Colloids and Surfaces B: Biointerfaces》;20170101;第 149 卷;全文 *
Active targeting with Y-90 radiolabelled octreotate functionalized AGuIX ultra-small nano particles;M.MAURIN 等;《 NUCLEAR MEDICINE AND BIOLOGY 》;20140801;第 41卷;全文 *
Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment;Le Duc G 等;《 Cancer nanotechnology》;20140701;第 5 卷;全文 *
含有杂环基侧链的新型聚硅氧烷;周传健等;《化学通报》;20021218(第12期);全文 *

Also Published As

Publication number Publication date
US11857604B2 (en) 2024-01-02
FR3072281B1 (fr) 2020-12-04
FR3072281A1 (fr) 2019-04-19
TWI791640B (zh) 2023-02-11
AU2018347740A1 (en) 2020-04-30
CA3078763A1 (en) 2019-04-18
CN111565759A (zh) 2020-08-21
KR20200071754A (ko) 2020-06-19
WO2019073182A1 (fr) 2019-04-18
JP2020536907A (ja) 2020-12-17
TW201922225A (zh) 2019-06-16
EP3694560A1 (fr) 2020-08-19
JP7321151B2 (ja) 2023-08-04
AU2018347740B2 (en) 2022-10-20
US20200289623A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
CN111565759B (zh) 纳米载体及用途
Porrang et al. How advancing are mesoporous silica nanoparticles? A comprehensive review of the literature
Duan et al. Size-controlled synthesis of drug-loaded zeolitic imidazolate framework in aqueous solution and size effect on their cancer theranostics in vivo
Li et al. Emerging ultrasmall luminescent nanoprobes for in vivo bioimaging
Li et al. A pH-sensitive drug delivery system based on folic acid-targeted HBP-modified mesoporous silica nanoparticles for cancer therapy
De Crozals et al. Nanoparticles with multiple properties for biomedical applications: A strategic guide
Wei et al. Synthesis of chitosan-coated near-infrared layered double hydroxide nanoparticles for in vivo optical imaging
Tao Mesoporous silica-based nanodevices for biological applications
Ma et al. Rationally integrating peptide-induced targeting and multimodal therapies in a dual-shell theranostic platform for orthotopic metastatic spinal tumors
KR102736896B1 (ko) 실리카 나노입자를 합성하는 방법
EP2791254B1 (en) Functionalised silicon nanoparticles
Pasqua et al. Recent development, applications, and perspectives of mesoporous silica particles in medicine and biotechnology
Radhakrishnan et al. The emergence of nanoporous materials in lung cancer therapy
Zhang et al. Advances in functionalized mesoporous silica nanoparticles for tumor targeted drug delivery and theranostics
Gupta et al. A review on recent technologies and patents on silica nanoparticles for cancer treatment and diagnosis
Muhammad et al. Lethal drug combination: arsenic loaded multiple drug mesoporous silica for theranostic applications
Shariatinia Inorganic material‐based nanocarriers for delivery of biomolecules
Iriarte-Mesa et al. Tailored mesoporous silica nanoparticles for overcoming gastrointestinal barriers: a perspective on advanced strategies for oral delivery
Almatroudi Advances in Mesoporous Silica and Hybrid Nanoparticles for Drug Delivery: Synthesis, Functionalization, and Biomedical Applications
Kanyuk Use of nanodiamonds in biomedicine
Rana et al. Porous silica nanoparticles for targeted bio-imaging and drug delivery applications
Li et al. Boron nitride nanotubes as drug carriers
Wang et al. Engineered upconversion nanoparticles for breast cancer theranostics
CN116472067A (zh) 用于制备纳米颗粒的方法
El‐Dakdouki et al. Methods for magnetic nanoparticle synthesis and functionalization

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201224

Address after: Fa Guomeilang

Applicant after: NH agix treatment

Address before: Fa Guomeilang

Applicant before: NH agix treatment

Applicant before: University CLAUDE BERNARD LYON

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant